Please assess the completion status of the following clinical trial:

Trial Title: Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease~Exclusion Criteria:~* known allergies to aspirin, clopidogrel, or cilostazol thienopyridine use before enrollment~* concomitant use of other anti-thrombotic drugs (oral anticoagulants and dipyridamole)~* platelet count \<100 x 106/μL~* hematocrit \< 25%~* liver disease (bilirubin \> 2 mg/dl)~* active bleeding or bleeding diathesis~* gastrointestinal bleeding within the last 6 months~* hemodynamic instability~* acute coronary or cerebrovascular event within 3 months~* malignancy~* concomitant use of a cytochrome P450 inhibitor or a non-steroidal anti-inflammatory drug~* recent treatment (\<30 days) with a glycoprotein IIb/IIIa antagonist.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- clopidogrel 75 mg/day (Type: ACTIVE_COMPARATOR): CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
- clopidogrel 150 mg/day (Type: ACTIVE_COMPARATOR): CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
- adjunctive cilostazol (Type: ACTIVE_COMPARATOR): CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; \[group 3, 20 patients\]) for 14 days.
- 75mg clopidogrel (Type: ACTIVE_COMPARATOR): control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).